Skip to main content
Journal cover image

A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Publication ,  Conference
Tran, B; Kouros-Mehr, H; Fermin, A; Horvath, L; Roncolato, F; Rettig, M; Dorff, T; Tagawa, ST; Subudhi, SK; Antonarakis, ES; Armstrong, AJ ...
Published in: ANNALS OF ONCOLOGY
October 1, 2019

Duke Scholars

Published In

ANNALS OF ONCOLOGY

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2019

Volume

30

Start / End Page

353 / 353

Location

Barcelona, SPAIN

Publisher

OXFORD UNIV PRESS

Conference Name

44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tran, B., Kouros-Mehr, H., Fermin, A., Horvath, L., Roncolato, F., Rettig, M., … Scher, H. I. (2019). A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In ANNALS OF ONCOLOGY (Vol. 30, pp. 353–353). Barcelona, SPAIN: OXFORD UNIV PRESS.
Tran, B., H. Kouros-Mehr, A. Fermin, L. Horvath, F. Roncolato, M. Rettig, T. Dorff, et al. “A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).” In ANNALS OF ONCOLOGY, 30:353–353. OXFORD UNIV PRESS, 2019.
Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, et al. A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019. p. 353–353.
Tran B, Kouros-Mehr H, Fermin A, Horvath L, Roncolato F, Rettig M, Dorff T, Tagawa ST, Subudhi SK, Antonarakis ES, Armstrong AJ, Petrylak DP, Fizazi K, Salvati ME, Scher HI. A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2019. p. 353–353.
Journal cover image

Published In

ANNALS OF ONCOLOGY

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2019

Volume

30

Start / End Page

353 / 353

Location

Barcelona, SPAIN

Publisher

OXFORD UNIV PRESS

Conference Name

44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis